International Journal of Science and Research (IJSR)
ISSN: 2319-7064
Impact Factor 2025: 7.089

Platelets as Endogenous Cellular Adaptogens: A Review of Stress Signaling and Regenerative Implications

Tapley Holland

Panama College of Cell Science, Azuero Business Center, Suite 758, Avenida Perez Chitre, 00395, Panama
Corresponding Author Email: *tapley[at]trudose.com*

Abstract: ***This review examines platelets as multifunctional regulators of stress adaptation, extending their role beyond hemostasis to include immune modulation, metabolic coordination, and tissue repair. Drawing on literature from stress physiology, platelet signaling, and regenerative medicine, the paper proposes that platelets exhibit key characteristics of adaptogenic systems, including bidirectional regulation and context-dependent signaling across alarm, resistance, and exhaustion phases of stress. Evidence from platelet biology and emerging clinical studies of platelet-rich plasma is discussed in relation to chronic inflammatory and exhaustion-associated conditions. The analysis highlights mechanistic pathways through which platelets influence homeostasis and regenerative responses and considers their therapeutic relevance in environments where conventional regenerative approaches may be constrained. Together, the review presents a unified perspective on platelet-mediated stress adaptation and its implications for systemic regenerative strategies.***

Keywords: Platelet signaling, Stress adaptation, Regenerative medicine, Platelet-rich plasma, Cellular resilience

1. Introduction

The purpose of this paper is to examine the role of platelets in stress adaptation and tissue repair, extending their traditional classification beyond hemostasis to include broader functions in immune regulation, metabolic signaling, and systemic resilience. Stress adaptation is a fundamental biological process required for survival and recovery across all levels of organization, and dysregulation of these adaptive processes contributes to chronic inflammation, metabolic dysfunction, impaired regeneration, and stress-related disease states. Emerging evidence indicates that platelet signaling exhibits key characteristics of adaptogenic mechanisms, including bidirectional regulation and the capacity to restore homeostasis under variable stress conditions.

Accordingly, this paper synthesizes current literature on platelet biology, stress physiology, metabolic adaptation, and regenerative medicine to propose a unifying framework in which platelets function as endogenous cellular adaptogens. This perspective contributes to current discussions in regenerative biology by reframing platelets as systemic regulators of stress adaptation, thereby expanding conceptual models of cellular resilience beyond traditional stem-cell centered paradigms.

2. Methods

This review was conducted as a structured narrative synthesis. Literature searches were performed using PubMed, Google Scholar, and supplementary searches via Google to identify relevant peer-reviewed publications. Keywords and search terms included: *"stress healing," "stress adaptation," "adaptogens," "botanical adaptogens," "cellular adaptogens", platelet biology "platelets," "platelet metabolism," "platelet activation," "platelet signaling," "platelet secretome," "platelet-derived extracellular vesicles," "platelet–immune interactions," "intracellular and extracellular platelet signaling", "stem cells," "tissue repair," "wound healing," "regenerative medicine," "homeostasis," "allostasis," "chronic stress," "systems biology"*.

Articles were included if they were original research studies, mechanistic investigations, translational studies, or otherwise directly relevant to the review scope. Opinion-based, non-peer-reviewed, or non-verifiable sources were excluded. Titles and abstracts were screened for relevance, followed by full-text review to confirm alignment with the scope of adaptive signaling, bidirectional regulation, and systemic homeostasis. The search primarily focused on studies published between 2000 and 2025; however, reference lists of included articles also identified seminal or highly relevant studies published prior to 2000, which were included to provide historical context and foundational understanding of stress adaptation. All selected studies underwent qualitative thematic synthesis and are presented in this review.

3. Results

This review identifies platelets as intrinsic, multifunctional effectors capable of orchestrating adaptive repair across all phases of the stress response, positioning them as the body's endogenous cellular adaptogen. Platelets exhibit extracellular and intracellular mechanisms that mirror, and in many cases surpass, the multitarget, context-dependent effects of botanical adaptogens. Historically underexplored for complex, multisystem disease applications, platelet-based therapies contrast with stem cell strategies, which may be limited under exhaustion-phase conditions characterized by metabolic insufficiency, chronic inflammation, impaired niche signaling, and reduced cellular responsiveness. Platelets are uniquely equipped to operate in hostile or resource-limited microenvironments, relying on rapid sensing, adaptive signaling, and context-dependent responses rather than engraftment or long-term survival. Through the release of cytokines, chemokines, growth factors, and extracellular vesicles, platelets coordinate immune

modulation, angiogenesis, tissue repair, and systemic homeostasis. Preclinical and early clinical studies demonstrate that systemic platelet-rich plasma (PRP) can improve neurocognition, vascular repair, and inflammatory profiles with minimal adverse effects. Dose-dependent effects align with adaptogenic principles, highlighting the importance of precise platelet dose administration. Collectively, these findings support platelets as rapid, multifunctional effectors capable of addressing complex, multisystem, and exhaustion-phase pathologies where conventional regenerative strategies may be limited.

1) Stress, Healing, and the Search for Resilience

"Without healing, multicellular life on Earth would not exist. Without healing, one injury predisposes to another, leading to disability, chronic disease, accelerated aging, and death" [1]. Living organisms are continuously exposed to environmental, physiological, and psychological stressors that challenge cellular integrity and functional stability; however, health is maintained not by the absence of stress, but by the capacity of biological systems to sense these perturbations, mount appropriate adaptive responses, and restore homeostasis after the challenge. Biological healing encompasses a wide array of restorative processes, including wound repair, immune recovery from infections, tissue regeneration, cellular damage repair, and overall recovery from illness or injury, all of which occur within inherently non-linear, cyclical, and dynamic systems characterized by cellular responses and adaptations essential for survival in a continually evolving environment. Traditional wound-healing models emphasize macroscopic physiological stages—hemostasis, inflammation, proliferation, and remodeling- yet often fail to capture the dynamic, multifaceted interplay of cellular and molecular mechanisms that govern healing under stress, thereby limiting understanding of chronic wounds and stress-associated systemic diseases. In contrast, Hans Selye's General Adaptation Syndrome (GAS) provides a more integrative framework for elucidating the cellular mechanisms underlying biological healing by situating molecular repair processes within systemic neuroendocrine and inflammatory stress responses. By linking cellular adaptation to organism-wide adaptive capacity, GAS explains how homeostasis is actively maintained under acute stress while revealing how prolonged or excessive stress drives maladaptation, impaired repair, and disease. This perspective is essential for understanding healing not as a static sequence of events, but as a dynamic, stress-modulated process governed by the balance between adaptive reserve and cumulative load. Within this framework, adaptive effectors that can sense stress, integrate systemic and local signals, and actively coordinate repair across phases of stress emerge as central determinants of regenerative capacity- providing the conceptual foundation for examining the adaptogenic properties of platelets and their potential role in regenerative medicine.

2) Stress Healing and the General Adaptation Syndrome (GAS)

Stressors- whether physical, emotional, environmental, or biological- initiate conserved cellular and systemic responses aimed at preserving homeostasis. Hans Selye's General Adaptation Syndrome (GAS) conceptualizes stress adaptation as a dynamic, staged healing process comprising alarm, resistance, and exhaustion, through which organisms detect perturbations, mobilize adaptive resources, and either restore functional balance or progress toward dysfunction when adaptive capacity is exceeded. The GAS concept emerged from Selye's observation of a nonspecific stress syndrome, in which diverse damaging stimuli- including chemical intoxication, surgical injury, thermal exposure, excessive physical exertion, infectious agents, and psychological stress- elicited a common biological response pattern [2,3].

The alarm stage represents the immediate, acute response to stress, unfolding within seconds to hours after stressor detection and corresponding to the classical fight-or-flight reaction [4,5]. During this phase, homeostasis is intentionally disrupted to prioritize survival, rapidly mobilizing energy and defensive resources [6]. Extracellularly, alarm is driven by activation of the neuroendocrine stress system, particularly the hypothalamic–pituitary–adrenal (HPA) axis and the sympathetic–adrenal medullary system. Hypothalamic release of corticotropin-releasing hormone (CRH) stimulates pituitary secretion of adrenocorticotropic hormone (ACTH), culminating in adrenal release of cortisol and catecholamines such as adrenaline and noradrenaline [7,8]. These circulating mediators rapidly engage glucocorticoid and adrenergic receptors across tissues, producing systemic effects including increased cardiac output, energy substrate mobilization, redistribution of immune cells to barrier sites, and transient modulation of cytokine secretion for early immune surveillance [6,9]. Intracellularly, alarm-phase signaling is characterized by rapid receptor-mediated activation of second messenger systems, including G-protein coupled receptors and ion channels such as transient receptor potential (TRP) channels, which trigger calcium influx and downstream kinase cascades (e.g., MAPK, JNK, p38) [10]. These pathways rapidly regulate transcription factors such as NF-κB and AP-1, initiating early stress-response gene expression, including pro-survival and inflammatory mediators. Concurrently, heat shock proteins (e.g., Hsp70) and antioxidant defenses are transiently upregulated to stabilize protein structures, protect mitochondrial function, and limit reactive oxygen species (ROS)-induced damage during acute stress exposure [10,11]. These intracellular mechanisms work in concert with extracellular neuroendocrine and paracrine signals to ensure that cells and tissues respond rapidly to the stressor while minimizing premature damage.

The resistance stage ensues when stressors persist beyond the acute phase, typically over days to weeks, and reflects the organism's capacity to adapt, restore balance, and sustain defense while ongoing challenges remain [5,6]. During this phase, stress responses are recalibrated rather than maximized, allowing healing and functional maintenance at the cost of diverting resources from nonessential processes such as growth and reproduction [12]. Extracellular neuroendocrine signaling becomes stabilized, with cortisol maintained at elevated yet regulated levels that support adaptation without triggering overt pathology [7,8]. In parallel, extracellular redox signaling is tightly regulated through gaseous mediators such as nitric oxide and hydrogen sulfide, as well as controlled reactive oxygen species (ROS) generation by NAD(P)H oxidases, enabling adaptive intercellular communication and vascular, immune, and metabolic coordination without inducing oxidative injury

[13,14], while tissue repair is reinforced through fibroblast-mediated collagen synthesis and extracellular matrix remodeling to maintain structural integrity and functional recovery [15]. At the cellular level, the resistance phase is characterized by coordinated intracellular signaling and transcriptional regulation that shifts pathways from proinflammatory activation toward controlled modulation. Glucocorticoid receptor signaling induces anti-inflammatory mediators such as annexin A1 while suppressing excessive activation of transcription factors including NF-κB and AP-1, thereby restraining inflammation without compromising adaptive defense [16,17]. Concurrently, immune modulation reflects a transition from acute inflammation toward resolution and repair: macrophages increasingly adopt anti-inflammatory, pro-repair phenotypes, while cellular maintenance mechanisms- including autophagy and DNA repair pathways—remove damaged components and preserve genomic stability [18,19]. This bidirectional regulation fine-tunes cellular metabolism, favoring sustained energy production through lipid oxidation and mitochondrial oxidative phosphorylation to support prolonged stress tolerance [6,20]. Antioxidant and cytoprotective systems are upregulated to limit cumulative cellular damage, with enzymes such as superoxide dismutase, catalase, and glutathione peroxidase mitigating ROS accumulation, while heat shock proteins (Hsp70, Hsp90) preserve proteostasis and facilitate protein refolding [10,11]. Central to these protective responses is the transcription factor Nrf2 (nuclear factor erythroid 2–related factor 2), which translocates to the nucleus and activates antioxidant response element (ARE) genes—including HO-1, NQO1, and glutathione-related enzymes- enhancing redox buffering, detoxification capacity, mitochondrial integrity, and metabolic efficiency. Through Nrf2-mediated transcriptional control, cells stabilize energy metabolism, maintain proteostasis, and reinforce resilience during prolonged stress exposure, delaying progression toward exhaustion and preserving adaptive capacity [21,22]. Collectively, the resistance stage represents a period of enhanced extracellular and intracellular adaptive signaling, immune modulation, and cellular stress tolerance that often exceeds baseline capacity [6]. However, prolonged activation consumes molecular and energetic reserves, leaving the organism vulnerable to exhaustion if stressors persist or regulatory balance fails [5,12]. This sets the stage for the exhaustion phase, where impaired adaptation and cumulative damage challenge the organism's ability to maintain homeostasis and repair.

The exhaustion stage arises when stressors persist beyond the organism's adaptive capacity, resulting in widespread cellular dysfunction, tissue damage, and systemic breakdown of homeostasis [5,6]. Neuroendocrine regulation is profoundly impaired: chronic HPA axis activation leads to glucocorticoid receptor desensitization and disrupted cortisol feedback, allowing persistent inflammatory signaling [7,23]. This dysregulation further compromises immune function, producing cytokine imbalance, reduced phagocytic activity, impaired adaptive responses, and sustained NF-κB activation, collectively slowing pathogen clearance and tissue repair [24-26]. Epigenetic modifications, including DNA methylation and histone modifications, sustain maladaptive gene expression and reinforce dysfunctional stress responses [27,28]. At the cellular level, exhaustion is marked by mitochondrial dysfunction and oxidative stress. Mitochondria produce excessive reactive oxygen species (ROS) while ATP generation declines, disrupting energy homeostasis and impairing cellular survival programs [13,29]. Protective transcription factors such as Nrf2 fail to adequately translocate to the nucleus, limiting activation of antioxidant response element (ARE) genes—including glutathione peroxidase, superoxide dismutase, catalase, heme oxygenase-1 (HO-1), and NAD(P)H quinone oxidoreductase 1 (NQO1)-which normally restore redox balance, protect mitochondria, and enhance detoxification. These intracellular deficits exacerbate immune compromise, limiting leukocyte responsiveness, inflammatory resolution, and effective coordination of reparative signaling. The resulting redox imbalance accelerates macromolecular damage, compromises mitochondrial integrity, and diminishes metabolic flexibility. Senescent cells accumulate during exhaustion and adopt a senescence-associated secretory phenotype (SASP), secreting extracellular proinflammatory cytokines (e.g., IL-6, IL-1β, TNF-α), chemokines, and matrix-degrading enzymes. SASP factors propagate chronic inflammation, disrupt extracellular matrix structure, impair tissue repair, and inhibit regenerative processes [30-32]. Cellular maintenance pathways- including autophagy and proteostasis mechanisms—are overwhelmed, allowing damaged organelles and misfolded proteins to accumulate, which further promotes cellular dysfunction and accelerates tissue aging. At the tissue and organ level, exhaustion manifests as delayed wound healing, impaired angiogenesis, reduced collagen synthesis, compromised tissue remodeling, and diminished neuroplasticity, reflecting the cumulative effects of chronic inflammation, impaired immune surveillance, and SASP-mediated matrix disruption [6,15]. The exhaustion phase represents the collapse of both extracellular and intracellular adaptive networks: cells can no longer maintain energy homeostasis, mitigate oxidative damage, or coordinate effective repair. The accumulation of senescent cells, redox imbalance, mitochondrial dysfunction, and proteostasis failure collectively generate a systemic environment of chronic inflammation and impaired regenerative capacity, underscoring the need for interventions that restore cellular resilience, metabolic flexibility, and homeostatic balance.

Taken together, the alarm, resistance, and exhaustion phases illustrate that stress responses are not inherently pathological but become damaging when adaptive capacity is exceeded or dysregulated over time. This framework emphasizes the importance of therapies that extend the resistance phase, prevent progression to exhaustion, and actively support systemic resilience. Within this context, adaptogens- both botanical and cellular- emerge as agents capable of enhancing adaptive capacity, stabilizing homeostatic control, and orchestrating coordinated repair across multiple biological systems.

3) Botanical Adaptogens

Adaptogens are a class of botanical agents historically identified across diverse medical traditions for their ability to enhance resilience, accelerate recovery, and preserve functional capacity under conditions of physical, chemical, and psychological stress. Long before the molecular basis of stress adaptation was understood, these plants were empirically observed to normalize physiological function,

increase resistance to a broad range of stressors, and support long-term homeostasis without causing overstimulation or suppression. Contemporary research has demonstrated that adaptogens exert their effects through multitarget, systems-level modulation of conserved stress-response networks, including neuroendocrine, immune, and metabolic pathways [33-35]. Rather than acting as direct agonists or antagonists, adaptogens fine-tune stress signaling by regulating hypothalamic–pituitary–adrenal (HPA) axis activity, balancing pro- and anti-inflammatory cytokine production, and supporting cellular energy homeostasis in a context-dependent and self-limiting manner [33]. Through coordinated extracellular and intracellular signaling, these agents bias cellular responses toward survival, metabolic efficiency, controlled inflammatory activity, and repair, thereby enhancing resistance-phase biology and reducing progression toward stress-induced exhaustion as described by the General Adaptation Syndrome [5,35]. Collectively, the convergence of historical use, clinical observation, and emerging molecular evidence supports the classification of adaptogens as modulators of adaptive healing processes that promote organismal resilience rather than single-target pharmacological effects.

4. Adaptogen Stress Response Signaling

Adaptogens exert multitarget effects by modulating both extracellular and intracellular signaling networks to support stress adaptation, immune function, and tissue repair. Rather than directly altering the General Adaptation Syndrome phases, adaptogens fine-tune molecular and cellular responses, ensuring that alarm-phase survival mechanisms transition efficiently into resistance-phase recovery and adaptive repair.

4.1 Extracellular Stress Response

At the extracellular level, adaptogens regulate neuroendocrine mediators, cytokines, chemokines, purinergic signals, and growth factor pathways that collectively shape systemic stress responses and tissue microenvironments. They attenuate excessive cortisol and catecholamine release while preserving essential immune and metabolic signaling. Botanical adaptogens including *Rhodiola rosea*, *Panax ginseng*, *Withania somnifera*, *Eleutherococcus senticosus*, *Schisandra chinensis*, *Bacopa monnieri*, *Ocimum sanctum*, *Astragalus membranaceus*, and *Glycyrrhiza glabra* modulate hypothalamic–pituitary–adrenal (HPA) axis activity, sympathetic output, and adrenergic receptor signaling [33-37]. Through this regulation, adaptogens prevent excessive early hyperactivation that could otherwise accelerate inflammatory cascades or promote premature cellular exhaustion.

Adaptogens also normalize extracellular immune signaling by modulating proinflammatory cytokines (IL-6, IL-1β, TNF-α), enhancing anti-inflammatory mediators (IL-10, TGF-β), and stabilizing chemokine gradients (CXCL4/PF4, CCL5/RANTES, CXCL12/SDF-1) [34-38]. This coordinated regulation supports appropriate trafficking of macrophages, neutrophils, and lymphocytes while preventing sustained hyperinflammation. These effects intersect with purinergic signaling, as adaptogens indirectly support ATP/ADP sensing and extracellular adenosine accumulation, promoting inflammation resolution, endothelial stabilization, and tissue repair [39,40]. At the tissue level, these extracellular effects translate into enhanced structural repair and functional recovery. Adaptogens support fibroblast activation, collagen synthesis, angiogenesis, and extracellular matrix remodeling, reinforcing tissue resilience and regenerative capacity. Botanical examples include *Panax ginseng*, *Schisandra chinensis*, *Withania somnifera*, and *Centella asiatica* [33,36,41]. By optimizing extracellular signaling environments, adaptogens help ensure that acute alarm-phase responses resolve into resistance-phase adaptation and repair rather than progressing toward chronic dysfunction.

4.2 Intracellular Stress Response

Within cells, adaptogens modulate kinase cascades, transcriptional programs, redox balance, mitochondrial function, and proteostasis- directly influencing cellular energy homeostasis and stress resilience. Key kinase networks, including MAPK/ERK, JNK, p38, PI3K–Akt, and AMPK, integrate hormonal, metabolic, and oxidative cues to regulate cell survival and adaptation. Adaptogens such as *Rhodiola rosea*, *Panax ginseng*, *Withania somnifera*, *Eleutherococcus senticosus*, and *Schisandra chinensis* stabilize these pathways, promoting stress resistance, controlled proliferation, protection from apoptosis, and enhanced metabolic flexibility [33,35]. Activation of AMPK, in particular, improves ATP efficiency during prolonged stress, conserving cellular energy reserves.

A central intracellular node regulated by adaptogens is the transcription factor Nrf2, which induces antioxidant response element (ARE) genes- including glutathione peroxidase, superoxide dismutase, catalase, heme oxygenase-1 (HO-1), and NAD(P)H quinone oxidoreductase 1 (NQO1). Adaptogens such as *Withania somnifera*, *Rhodiola rosea*, *Schisandra chinensis*, *Panax ginseng*, *Curcuma longa*, *Bacopa monnieri*, and *Glycyrrhiza glabra* support Nrf2 signaling, reinforcing intracellular antioxidant defenses and protecting mitochondrial integrity under stress [33,35,37]. Inflammatory tone is further regulated through modulation of NF-κB and AP-1 transcription factors. Adaptogens attenuate excessive NF-κB activation while preserving necessary immune responsiveness, distinguishing them from single-target anti-inflammatory drugs [33,38]. Mitochondrial function is preserved through stabilization of the electron transport chain, maintenance of membrane potential, and controlled reactive oxygen species signaling, allowing ROS to function as secondary messengers rather than drivers of damage [35]. Adaptogens also reinforce intracellular repair and quality-control systems. Heat shock proteins (Hsp70, Hsp90) maintain proteostasis and facilitate protein refolding, while autophagy removes damaged organelles and misfolded proteins. *Panax ginseng*, *Withania somnifera*, *Schisandra chinensis*, and *Bacopa monnieri* enhance these pathways, preserving cellular integrity and enabling functional renewal during prolonged stress [34].

While botanical adaptogens effectively reinforce conserved intracellular stress-response pathways and help sustain the resistance phase of the General Adaptation Syndrome, their actions remain fundamentally modulatory and dependent on intact cellular and systemic infrastructure. Adaptogens

influence signaling networks indirectly, fine-tuning kinase cascades, redox balance, and transcriptional programs such as Nrf2 and NF-κB, but they do not themselves constitute active cellular agents of repair. As stress burden accumulates and adaptive capacity becomes strained- particularly under conditions of tissue injury, chronic inflammation, or metabolic dysfunction- the limitations of purely phytochemical modulation become most apparent in the exhaustion phase: botanical adaptogens cannot restore mitochondrial energy production in metabolically compromised cells, remove senescent cells or neutralize their proinflammatory SASP factors, directly resolve chronic oxidative stress, or coordinate multi-tissue repair, leaving systemic homeostasis increasingly vulnerable. Within this context, platelets emerge as uniquely positioned mediators of adaptive healing. Long regarded primarily as effectors of hemostasis, platelets are now recognized as highly responsive, multifunctional cellular units that integrate extracellular sensing with intracellular signaling programs to regulate inflammation, metabolism, tissue repair, and systemic homeostasis. Unlike botanical adaptogens, which act upstream or in parallel to cellular stress responses, platelets operate as endogenous, mobile effectors capable of directly translating stress signals into coordinated regenerative action. The following section explores how platelets function as intrinsic cellular adaptogens, bridging extracellular communication and intracellular resilience to support adaptive repair across all stages of the stress response.

5. The Conventional Understanding and Therapeutic Use of Platelets

Platelets, also known as thrombocytes, have conventionally been understood as anucleate cell fragments derived from megakaryocytes in the bone marrow, primarily functioning as key effectors in hemostasis and thrombosis. In this traditional view, their main role is to respond to vascular injury by adhering to exposed subendothelial collagen via receptors such as glycoprotein VI (GPVI) and integrin α2β1, leading to activation, shape change, and release of granule contents including ADP, thromboxane A_2, and fibrinogen, which promote platelet aggregation and clot formation through the GPIIb/IIIa receptor complex [42,43].

Therapeutically, platelets have been widely investigated within Platelet-Rich Plasma (PRP) for over 30 years as a tool to enhance recovery after various surgical, orthopedic, and dental procedures, with thousands of studies examining their safety and effectiveness. In addition, a substantial body of literature has characterized PRP-enriched growth factors and cytokines, providing a detailed understanding of platelets' regenerative potential across multiple medical disciplines. The rationale underlying PRP therapy is that, as the body's natural healing agents, platelets contain growth factors and cytokines that can be concentrated and directed to injury sites to potentially accelerate repair. In site-specific PRP injections, an activation agent- such as thrombin, calcium chloride, or collagen—is used to stimulate platelet degranulation, facilitating the immediate, localized release of stored growth factors (e.g., PDGF, TGF-β, VEGF, EGF) directly at the target site for enhanced regenerative efficacy. The risk of clot formation is minimized because activation is limited to the localized injection area [44-49].

Rather than viewing platelet function solely as an immediate "burst" release system, in which activation prompts degranulation for localized repair, this perspective underestimates their broader adaptive regenerative capacities. Platelets operate as dynamic modulators and effectors, capable of influencing healing over extended periods beyond the initial stages of hemostasis and inflammation. They engage intracellular and extracellular signaling networks that extend their influence well beyond immediate clot formation. Extracellularly, platelets release cytokines, chemokines, growth factors, and extracellular vesicles, coordinating immune cell recruitment, angiogenesis, and tissue repair at local and systemic levels. Intracellularly, kinase cascades, calcium flux, and metabolic pathways allow platelets to sense stress, regulate energy homeostasis, and modulate their secretory profile in response to context-specific cues. These integrated signaling mechanisms underpin the paradoxical properties of platelets, enabling them to balance opposing processes- pro- versus anti-inflammatory, thrombotic versus reparative, and damage-sensing versus repair-orchestrating—across all stages of healing. Rather than functioning solely as static clotting agents, platelets exhibit paradoxical versatility, acting as context-dependent effectors capable of orchestrating adaptive responses far beyond classical hemostasis.

6. The Platelet Paradox

Platelets exhibit fundamentally paradoxical properties that allow them to exert context-dependent and often opposing biological effects within the same cell, reflecting a principle in which apparent contradictions reveal adaptive truth. This "platelet paradox" is exemplified clinically: paradoxical thrombosis can occur even in the presence of thrombocytopenia or impaired platelet function, as seen in conditions such as immune thrombocytopenia (ITP), common variable immunodeficiency, antiphospholipid syndrome, and myeloproliferative disorders (See Table 1). In these scenarios, compensatory hyperreactivity, immune dysregulation, or altered interactions with von Willebrand factor increase thrombotic risk despite reduced platelet counts [50,51]. Similarly, pharmacologic agents- including aspirin, glycoprotein IIb/IIIa inhibitors, and analgesics- or stressors such as shear stress, streptozotocin-induced diabetes, or SARS-CoV-2 infection can paradoxically enhance platelet activation, aggregation, or procoagulant activity, highlighting their non-linear and context-sensitive behavior.

Mechanistically, this paradox is underpinned by both intracellular and extracellular signaling networks. Italiano et al. demonstrated that pro-angiogenic mediators (e.g., VEGF, PDGF) and anti-angiogenic factors (e.g., thrombospondin-1, endostatin) are segregated into distinct α-granules and released in a stimulus-specific manner, allowing platelets to either promote vascular growth or restrain it depending on the tissue state [52]. Extracellularly, platelets release cytokines, chemokines, growth factors, and extracellular vesicles that coordinate immune recruitment, angiogenesis, and tissue repair, while intracellular kinase cascades, calcium flux, and metabolic pathways dynamically regulate energy sensing, secretory profiles, and adaptive responses.

This paradox extends across multiple biological domains. Platelets simultaneously drive thrombosis and hemostasis

while functioning as immune sentinels- expressing pattern recognition receptors, interacting with leukocytes, and shaping innate and adaptive immunity [53]. They can amplify acute inflammation through IL-1β, CXCL4, and CCL5 release, yet also promote resolution by stabilizing endothelial barriers, limiting leukocyte extravasation, and supporting

1	Imataki, O., et al. (2017)	*Paradoxical thrombosis in idiopathic thrombocytopenic purpura. International journal of hematology, 105(2) 111-112*
2	Mihalov, J., et al. (2016)	*A Seeming Paradox: Ischemic Stroke in the Context of Idiopathic Thrombocytopenic Purpura.* Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 22(2) 115-120
3	Dvoretsky L.I. (2021)	*Immune thrombocytopenia and thrombosis. Hematological paradox or clinical reality?.* Consilium Medicum, 23(6) 463-468
4	Trogen, B., et al. (2025)	*The paradox of autoimmune thrombocytopenia in common variable immunodeficiency.* British Journal of Haematology, 206(6) 1582-1584
5	Ong, C. Y., et al. (2017)	*Thrombotic Paradox: Ischaemic Stroke in Immune Thrombocytopaenia. A Case Report and Review.* Cureus, 9(12) e1904
6	Jain, A., et al. (2019)	*Recurrent Arterial and Venous Thrombosis in Chronic Immune Thrombocytopenia: Clinical Paradox and Therapeutic Challenges.* Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 35(3) 590-592
7	Rasheed, M. A., et al. (2020)	*Cerebral venous thrombosis in a patient with immune thrombocytopenia, an apparent paradox.* Case Reports in Oncology, 13(2) 588-594
8	de la Cruz-Benito, B., et al. (2021)	*Paradoxical effect of SARS-CoV-2 infection in patients with immune thrombocytopenia.* British journal of haematology, 192(6) 973-977
9	Michiels, J. J., et al. (2006)	*The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.* Seminars in thrombosis and hemostasis, 32(6) 589-604.
10	Kleinbongard, P., et al. (2021)	*The platelet paradox of injury versus protection in myocardial infarction-has it been overlooked?.* Basic research in cardiology, 116(1) 37.
11	Scridon, A., et al. (2019)	*STREPTOZOTOCIN-INDUCED DIABETES MELLITUS - A PARADOX OF HIGH INTRINSIC PLATELET REACTIVITY AND LOW IN VITRO PLATELET AGGREGATION.* Acta endocrinologica (Bucharest, Romania : 2005), 5(1) 46-51
12	Boughton, B. J., et al. (1977)	*Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function.* Journal of clinical pathology, 30(3) 228-234
13	Sharp, D. S., et al. (2005)	*Platelet aggregation in whole blood is a paradoxical predictor of ischaemic stroke: Caerphilly Prospective Study revisited.* Platelets, 16(6) 320-328
14	Myers, R. A., et al. (2022)	*Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function.* British journal of clinical pharmacology, 88(5) 2074-2083
15	Chen, Z., et al. (2016)	*Paradoxical Effect of Nonphysiological Shear Stress on Platelets and von Willebrand Factor. Artificial organs, 40(7) 659-668*
16	Serebruany, V. L., et al. (2006)	*Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events?.* The American journal of medicine, 119(8) 707.e11–707.e7.07E16
17	Bassler, N., et al. (2007)	*A Mechanistic Model for Paradoxical Platelet Activation by Ligand-Mimetic αIIbβ3 (GPIIb/IIIa) Antagonists.* Arteriosclerosis, Thrombosis, and Vascular Biology, 27(3) E9-E15
18	Schneider, D. J., et al. (2000)	*Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.* Cardiovascular research, 45(2) 437–446
19	Weber, A. A., et al. (2002)	*Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.* Thrombosis research, 106(1) 25–29
20	Moro, M. A., et al. (1994)	*Paradoxical fate and biological action of peroxynitrite on human platelets.* Proceedings of the National Academy of Sciences of the United States of America, 91(14) 6702–6706
21	Ames, P. R. J., et al. (2023)	*Thrombocytopaenia in antiphospholipid syndrome: a free radical perspective.* Rheumatology (Oxford, England), 62(6) 2070–2075
22	Tomasello, R., et al. (2021)	*Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?.* Biomedicines, 9(9) 1170
23	Chapiolkina, V., et al. (2024)	*A Paradox Unveiled: A Case Report of Cerebral Infarctions in a Patient With Severe Thrombocytopenia.* Cureus, 16(7) e65283
24	Koike, T. (2005)	*Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis.* Lupus, 14(7) 499–504
25	Badulescu, O. V., et al. (2024)	*Thrombotic disease in hemophilic patients: Is this a paradox in a state of hypocoagulability?* Diagnostics, 14(3) 286
26	Hassan, Z., et al. (2021)	*Spinal cord infarction in a patient with immune thrombocytopenic purpura: A case report.* Spinal Cord Series and Cases, 7(1) 85
27	Ali, E. A., et al. (2022)	*Immune thrombocytopenic purpura and paradoxical thrombosis: A systematic review of case reports.* Cureus, 14(10) e30279
28	Neal, M. D. (2020)	*The great platelet paradox: Evolution of platelet contribution to hemostasis, inflammation, and thrombosis after injury.* Blood Advances, 4(11) 2556–2557
29	Kleinbongard, P., et al. (2021)	*The platelet paradox of injury versus protection in myocardial infarction—has it been overlooked?.* Basic research in cardiology, 116(1) 37

Table. 1 A literature search using the key words "Paradox" and Platelets" identified 29 relevant studies, compiled in this table as a comprehensive overview of paradoxical phenomena in platelet biology, including thrombosis in thrombocytopenia, platelet activation anomalies, and conflicting roles in hemostasis and inflammation, organized alphabetically by lead author for hematological research reference.

macrophage polarization toward reparative phenotypes [54]. At the tissue level, platelets act as both damage sensors and repair orchestrators: rapidly detecting vascular disruption and danger signals, initiating clot formation and immune recruitment, and then coordinating angiogenesis, extracellular matrix remodeling, and tissue stabilization through regulated growth factor and extracellular vesicle release [52].

Together, these clinical and mechanistic observations establish platelets as highly adaptive, context-responsive regulators of systemic homeostasis. Their ability to balance opposing processes- thrombotic versus reparative, pro- versus anti-inflammatory, damage sensing versus tissue repair—within a single cellular unit positions them as paradoxical but essential mediators of biological transitions, orchestrating complex healing responses across all stages of injury and stress. This intrinsic duality enables platelets to respond dynamically to stress and injury. In doing so, they contribute to the modulation of systemic resilience over time, reflecting the multitarget, context-dependent properties characteristic of botanical adaptogens. Through their ability to balance opposing processes and orchestrate complex repair programs, platelets provide a paradoxical cellular model of adaptive regulation, offering a conceptual bridge to their role as the body's sole endogenous cellular adaptogen.

7. Platelets: The Endogenous Cellular Adaptogen

7.1 Extracellular Platelet Signaling

Unlike botanical adaptogens, which act primarily through diffuse, systemic neuroendocrine, metabolic, and antioxidant

modulation over hours to days, platelets operate as rapid, site-specific effectors capable of sensing and responding to stress signals in real time. These acute-phase sensing and signaling networks allow platelets to detect the magnitude, timing, and context of stressors during the alarm phase and immediately translate local cues into precisely calibrated extracellular responses that shape downstream resistance and exhaustion outcomes.

Platelets communicate extensively with surrounding cells and tissues through extracellular mechanisms, coordinating immune responses, vascular homeostasis, and tissue repair far beyond their classical role in hemostasis and thrombosis. They secrete a broad repertoire of bioactive mediators, including pro- and anti-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-10), chemokines (CXCL4/PF4, CCL5/RANTES, CXCL12/SDF-1), and growth factors (PDGF, TGF-β, VEGF, EGF). In addition, platelets release extracellular vesicles (EVs) enriched with proteins, lipids, mRNAs, and microRNAs that deliver context-specific cargo to endothelial cells, fibroblasts, and immune cells, orchestrating angiogenesis, extracellular matrix remodeling, immune resolution, and tissue repair across the resistance phase of the General Adaptation Syndrome [54-56].

Critically, platelets uniquely integrate real-time extracellular sensing with immediate effector output, detecting local vascular injury, metabolic stress, hypoxia, or inflammatory danger signals and dynamically adjusting the magnitude, timing, and composition of their secretory responses. During the alarm phase, platelets respond within minutes to shear stress, ATP/ADP fluctuations, endothelial disruption, and damage-associated molecular patterns (DAMPs), rapidly deploying pro-hemostatic, immune-alerting, or barrier-stabilizing signals. As stress transitions into the resistance phase, platelet signaling shifts toward immune modulation, angiogenesis, matrix stabilization, and coordinated repair-functions that actively preserve adaptive capacity and delay progression toward exhaustion. Beyond soluble mediators, platelets regulate extracellular signaling through purinergic receptors—including P2X1, P2Y1, P2Y12, and adenosine A2A/A2B- which modulate calcium flux, integrin activation, granule exocytosis, and vesicle release in response to vascular, metabolic, and inflammatory stress. Chemokine signaling axes involving CXCL4, CCL5, and CXCL12 guide leukocyte recruitment, polarization, and trafficking while simultaneously reinforcing endothelial integrity and vascular homeostasis [39,40,53,57]. This tightly coupled sensing–response architecture enables platelets to fine-tune immune and vascular outputs across the alarm and resistance phases and to counteract maladaptive signaling that would otherwise accelerate exhaustion.

Through this combination of acute-phase sensing, receptor-mediated signaling, soluble mediator release, and extracellular vesicle trafficking, platelets function as dynamic, multitarget regulators of extracellular adaptive networks. Their speed, spatial precision, and context dependency allow them to coordinate tissue homeostasis, immune resolution, and regenerative repair under conditions of injury or stress in ways that botanical adaptogens- acting indirectly and systemically—cannot replicate. Together, these extracellular mechanisms establish platelets as central coordinators of organism-level adaptation across all phases of the GAS. Their effectiveness is inseparable from precisely tuned intracellular pathways governing calcium handling, kinase cascades, mitochondrial metabolism, and granule dynamics- setting the stage for their recognition as the body's sole endogenous cellular adaptogen.

7.2 Intracellular Platelet Signaling

Unlike botanical adaptogens, which primarily act through slower systemic modulation of neuroendocrine axes, redox status, and metabolism, platelets possess the ability to sense acute, minute-to-minute endocrine fluctuations and immediately translate them into functional cellular outputs, bridging organismal stress signals with targeted, adaptive intracellular responses. This capacity allows platelets to operate at the intersection of systemic stress signaling and localized cellular execution, providing a level of temporal precision and contextual responsiveness that botanical agents cannot achieve.

Intracellular signaling enables platelets to interpret stress and activation cues while coordinating survival, energy metabolism, vesicle trafficking, and functional output. Despite being anucleate, platelets maintain sophisticated intracellular networks that integrate kinase cascades, calcium flux, mitochondrial dynamics, NF-κB signaling [58], reactive oxygen species (ROS), and protein quality-control mechanisms to adapt to stress and sustain functional capacity [54,55,59]. During the alarm phase, these networks respond rapidly to acute vascular, inflammatory, or metabolic stress, initiating immediate activation, degranulation, and localized signaling. In the resistance phase, intracellular pathways sustain functional output over hours to days, coordinating energy metabolism, mitochondrial resilience, and cytokine and chemokine release to support adaptive repair and immune regulation. If stress persists into the exhaustion phase, intracellular homeostatic mechanisms may become overwhelmed, leading to reduced mitochondrial efficiency, impaired vesicle trafficking, and diminished functional output—underscoring the critical role of platelet adaptive capacity in preserving systemic resilience.

Key kinase cascades governing these processes include MAPK/ERK1/2, which regulates cytoskeletal reorganization, platelet spreading, and granule secretion [55]; p38 MAPK, which modulates stress responses and inflammatory mediator release [59]; JNK (c-Jun N-terminal kinase), activated by oxidative stress to regulate apoptosis-like signaling [59]; PI3K/Akt, which supports mitochondrial integrity, anti-apoptotic signaling, and vesicle trafficking [54]; and PKC, which governs granule release and integrin activation [55]. NF-κB signaling plays a particularly important role in platelets by regulating both pro- and anti-inflammatory responses, fine-tuning cytokine and chemokine release, and balancing immune surveillance with tissue repair during stress [59]. Together, these pathways coordinate the intracellular control of cytokines (IL-1β, IL-6, TNF-α, IL-10), chemokines (CXCL4/PF4, CCL5/RANTES, CXCL12/SDF-1), and growth factors (PDGF, TGF-β, VEGF, EGF), ensuring precise, context-dependent signaling.

Mitochondrial dynamics are central to platelet intracellular adaptation. Platelets regulate mitochondrial membrane potential to sustain ATP production, balance fission and fusion to preserve energy efficiency, and remove damaged mitochondria via mitophagy. Low-level ROS function as secondary messengers that modulate kinase and NF-κB activity without triggering apoptosis, while mitochondrial calcium uptake synchronizes energy production with the demands of degranulation and vesicle release. These mechanisms enable platelets to maintain functional activity across the alarm and resistance phases of stress, supporting prolonged immune, vascular, and tissue repair signaling [40,54].

Critically, platelet intracellular networks are tightly coupled to extracellular neuroendocrine inputs, including catecholamines (adrenaline and noradrenaline) and glucocorticoids. These hormones bind platelet surface receptors and rapidly modulate kinase cascades, calcium mobilization, integrin activation, and granule exocytosis, allowing platelets to translate systemic stress signals into localized intracellular responses in real time. This rapid coupling of endocrine sensing with intracellular execution allows platelets to modulate inflammation, vascular tone, and tissue repair with immediacy and spatial specificity during acute and chronic stress. Through these intracellular mechanisms, platelets mirror the multitarget, context-dependent intracellular pathways engaged by botanical adaptogens [33,38], but with unmatched temporal precision and integration of acute neuroendocrine cues across the alarm, resistance, and exhaustion phases of stress. By integrating intracellular signaling with extracellular communication networks, platelets function as endogenous cellular adaptogens—coordinating tissue repair, immune modulation, and systemic stress adaptation with a speed, specificity, and contextual intelligence that botanical agents cannot replicate.

8. Platelets: The Promising Exhaustion Phase Treatment

Regenerative medicine has been most successfully applied in acute and subacute settings, where endogenous repair mechanisms remain intact and inflammatory signaling is transient; however, its expanding promise lies in addressing exhaustion-phase disease states characterized by prolonged allostatic load and failed adaptive repair. Clinically, sustained exhaustion is associated with cardiovascular disease, metabolic syndrome, type 2 diabetes, neurodegeneration, chronic inflammatory disorders, and impaired wound healing, reflecting systemic consequences of chronic stress, immune dysregulation, and declining regenerative reserve [7,24,60]. At the cellular level, these conditions are marked by accumulation of senescent cells, immunosenescence, mitochondrial dysfunction, and a senescence-associated secretory phenotype (SASP) enriched in pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), matrix-degrading enzymes, and dysregulated growth factors (e.g., TGF-β, PDGF, VEGF), which collectively suppress stem cell function, impair tissue repair, and perpetuate chronic inflammation [30,31,61]. Within this context, stem cell–based therapies—particularly mesenchymal stem/stromal cells (MSCs)—have been explored as strategies to supplement exhausted regenerative systems. Clinical and translational studies across chronic wounds, cardiovascular disease, metabolic disorders, autoimmune conditions, and neurodegeneration indicate that MSCs can exert modest benefits through paracrine signaling, immune modulation, and angiogenic support rather than durable engraftment or tissue replacement [36,41,62]. Importantly, the defining features of exhaustion-phase pathology—chronic inflammation, disrupted intercellular communication, metabolic constraint, impaired cell survival, loss of paracrine and cell to cell communication and impaired regenerative signaling- are the very conditions under which stem cell–based therapies are theoretically most likely to fail. Although stem cell interventions can demonstrate regenerative potential under permissive conditions, therapeutic efficacy in chronic exhaustion disease states is often variable and transient, limited by hostile inflammatory microenvironments [63]. These factors highlight a central limitation of exogenous stem cell regenerative strategies in exhaustion-phase biology, thereby motivating the need for endogenous, stress-adapted cellular systems- such as platelets- that are intrinsically equipped to function, signal, and adapt under sustained physiological strain.

The integrated adaptive capacity of platelets highlights their unique therapeutic relevance in the exhaustion phase, where chronic stress has depleted cellular resilience and impaired coordinated repair. While botanical adaptogens remain effective during the alarm and resistance phases by modulating neuroendocrine, immune, and metabolic signaling, their actions are fundamentally indirect and contingent upon intact cellular infrastructure. In exhaustion-phase biology- characterized by disrupted energy metabolism, senescence-driven inflammatory signaling, oxidative burden, and suppressed regenerative capacity- phytochemical modulation alone is insufficient to reverse entrenched tissue-level dysfunction.

Underlying these effects is the notable metabolic adaptability of platelets. A systems-level reconstruction of human platelet metabolism (iAT-PLT-636) encompasses 1,008 intracellular reactions across glycolysis, oxidative phosphorylation, fatty acid metabolism, nucleotide salvage, amino acid pathways, and redox regulation, reflecting a level of biochemical complexity that rivals many nucleated cells [64]. Constraint-based modeling of this network demonstrates that platelets dynamically reroute metabolic flux through glycolysis, the pentose phosphate pathway, and lipid metabolism to sustain ATP production, manage reactive oxygen species (ROS), and support bioactive lipid and eicosanoid synthesis under stress conditions.

Platelets, by contrast, directly engage the molecular and metabolic deficits that define exhaustion. Through regulated secretion of growth factors (TGF-β, PDGF, VEGF), cytokines (IL-1β, IL-6, TNF-α), chemokines, and extracellular vesicles (EVs), platelets actively modulate the senescence-associated secretory phenotype (SASP) microenvironment. These secreted factors can neutralize excessive pro-inflammatory signaling by modulating NF-κB and STAT3 pathways in neighboring cells, thereby recalibrating inflammatory tone and reducing SASP-driven chronic inflammation [53,54]. Platelet-derived VEGF and PDGF stimulate endothelial proliferation and angiogenesis, restoring microvascular networks compromised by oxidative stress and inflammatory damage [55,65]. TGF-β and EV cargo influence extracellular

matrix (ECM) remodeling by activating fibroblasts and modulating collagen and matrix metalloproteinase (MMP) activity, correcting the ECM disorganization that impairs tissue repair in exhausted tissues [54,66].

Moreover, platelet EVs deliver microRNAs, mRNAs, and proteins that can reprogram senescent or metabolically impaired cells, enhancing mitochondrial function, reducing ROS accumulation, and promoting energy homeostasis [54,67]. This targeted signaling also restores stem cell responsiveness by counteracting SASP-mediated suppression of proliferation and differentiation, reactivating regenerative potential within chronically inflamed niches. Collectively, these platelet-mediated mechanisms provide a coordinated, multi-level correction of the cellular and molecular impairments characteristic of exhaustion-phase pathology, including chronic inflammation, oxidative stress, impaired angiogenesis, ECM disarray, and stem cell dysfunction.
Critically, emerging evidence demonstrates that platelet-based therapies can directly counter senescence-related cellular dysfunction. Liu et al. showed that platelet-rich plasma (PRP) recovered stem cell potential in aged mice by promoting proliferation and colony formation, enhancing osteogenic differentiation while suppressing adipogenesis, restoring senescence-associated molecular markers, and improving resistance to oxidative stress. These findings suggest that platelet-derived signaling not only modulates SASP-driven inflammation but can actively reverse functional aspects of cellular senescence and re-enable stem cell responsiveness within exhausted regenerative niches [68]. Collectively, these properties position platelets as uniquely capable of functioning within exhaustion-phase biology. By combining metabolic resilience, real-time stress sensing, and the capacity to counter senescence-driven signaling, platelets operate as endogenous, stress-adapted cellular systems capable of restoring adaptive repair under sustained physiological strain. This distinguishes platelet-based therapies from both botanical adaptogens and conventional regenerative approaches and underscores their potential to redefine regenerative medicine for chronic, exhaustion-phase disease states.

9. Discussion

As regenerative medicine advances under frameworks such as the 21st Century Cures Act, the U.S. Food and Drug Administration has established expedited regulatory pathways, including Regenerative Medicine Advanced Therapy (RMAT) designation, for therapies demonstrating preliminary clinical evidence indicating the potential to address serious conditions with unmet medical need [69,70]. This regulatory emphasis underscores the urgency for innovative therapeutic strategies in disease contexts that remain inadequately addressed by existing approaches. However, the physiological features that define exhaustion-based disease states—including metabolic insufficiency, chronic inflammation, impaired niche signaling, immune dysregulation, and diminished cellular responsiveness—may constitute biological conditions in which stem cell–based therapies are constrained, particularly when therapeutic efficacy depends on engraftment, differentiation, or sustained cellular viability. In contrast, platelets are inherently adapted to function within hostile, inflammatory, or resource-limited microenvironments. Their biological activity does not depend on long-term persistence, lineage commitment, or niche integration. Instead, platelets exert therapeutic influence through rapid environmental sensing, metabolic flexibility, and context-dependent signaling—properties that align closely with the pathophysiology of exhaustion-phase biology. These characteristics enable platelets to respond dynamically to fluctuating systemic conditions and to modulate tissue and immune responses without reliance on regenerative incorporation. Despite these attributes, platelet-based therapeutic strategies have historically been underexplored and frequently dismissed in the context of complex, multisystem disease, while regenerative paradigms centered on stem cell–based interventions have dominated translational and clinical development. Platelets demonstrate properties that extend beyond those traditionally attributed to botanical adaptogens, but the author has demonstrated that platelets function as the body's primary endogenous cellular adaptogen. This paper highlights specific mechanisms by which platelets act to address these unmet clinical needs- including bidirectional regulation, adaptive signaling, and the restoration of systemic homeostasis- illustrating their potential as a complementary or alternative regenerative strategy in conditions where conventional therapies, such as stem cell–based approaches, may be limited, and proposes the term "cellular adaptogen" to characterize this multidimensional functional paradigm.

Intravenous administration of PRP remains largely experimental, with the literature on systemic applications extremely scarce compared to the extensive use of local site-specific PRP injections, stem cell therapies, or other regenerative treatments. Nevertheless, emerging preclinical and early clinical evidence suggests that systemic PRP delivery can exert meaningful neuroregenerative, anti-inflammatory, and immunomodulatory effects with an acceptable safety profile- challenging the prevailing assumption that platelet therapies must act only locally. In preclinical models of aging and neurological injury, intravenous PRP demonstrated systemic efficacy, as evidenced by improved locomotion, learning, and memory in senescent mice without inducing anxiety- or depression-like behaviors, indicating central nervous system engagement following systemic exposure [71]. In a pediatric case of perinatal cerebral palsy, a single IV infusion of autologous PRP produced sustained improvements in cognition and functional performance, accompanied by increased circulating growth factors (IGF-1, PDGF, VEGF, TGF-β) and minimal adverse effects [72].

Beyond neurological indications, systemic or intravascular PRP delivery has shown promise in inflammatory and vascular conditions. In experimental ischemic stroke, intravenous PRP reduced infarct volume and improved functional recovery, consistent with platelet-mediated neuroprotection and angiogenesis [73]. Similarly, in equine chronic laminitis, repeated regional intravenous PRP combined with adipose-derived MSCs enhanced vascularization and tissue structure without reported adverse events [74]. Importantly, in severe and critical COVID-19 patients, intravenous activated autologous PRP significantly reduced circulating IL-1β levels and improved oxygenation (PaO_2/FiO_2 ratio), suggesting modulation of profibrotic and

hyperinflammatory signaling with favorable safety outcomes [75]. Across studies, IV PRP was generally well tolerated, with adverse events limited to minor, transient injection-site effects- demonstrating safety despite conventional concerns that systemic platelet administration might trigger unwanted clotting or thrombosis.

As with any therapeutic intervention, advancing systemic platelet-based treatments requires careful consideration of dosing parameters to achieve optimal efficacy and safety. The concept of dose-dependent efficacy in botanical adaptogens provides a valuable framework for understanding platelet-based interventions. Adaptogens typically exhibit hormetic, biphasic dose–response curves, where low to moderate doses stimulate adaptive stress pathways and enhance resilience, while higher doses may attenuate benefits or impair adaptive capacity [76]. If platelets function as endogenous cellular adaptogens, their therapeutic effects may similarly depend on achieving physiologically appropriate dosing that preserves integrated sensing, metabolic flexibility, and context-dependent effector functions. Systemic PRP therapies must therefore consider not only platelet concentration and volume, but also how dosing influences paracrine signaling, tissue responsiveness, and systemic adaptive capacity. Indeed, systemic spillover of platelet-derived growth factors following localized PRP injections has been documented [77], suggesting that tissues may require only a threshold stimulus to initiate meaningful adaptive responses and reinforcing the need for defined dosing paradigms that maximize both local and systemic benefits.

Finally, it is important to note that the conceptual framework advanced in this paper did not arise in isolation. The author has previously developed a device and accompanying methodology, TruDOSE™, designed to characterize and standardize platelet dosing for therapeutic applications. This platform has been applied clinically in thousands of treatments across diverse indications, generating extensive empirical observations regarding platelet behavior, dosing thresholds, and systemic responses. Although these outcomes have not yet been comprehensively reported in the scientific literature, they consistently demonstrate dose-dependent, context-responsive effects that align with adaptogenic biology rather than linear pharmacologic action. These observations served as the primary inspiration for the present work and motivated the formalization of platelets as endogenous cellular adaptogens within a unified biological framework.

10. Conclusion

In summary, this review integrates stress physiology, platelet biology, and regenerative medicine to propose a unified model in which platelets function as adaptive cellular regulators across phases of stress. Evidence from molecular signaling, metabolic modeling, and early clinical studies supports their capacity to influence inflammation, vascular repair, and tissue resilience under conditions of sustained stress. The largely unexplored adaptogenic capacities of platelets highlight their significant therapeutic potential, particularly for systemic, intravenous platelet-rich plasma as a regenerative strategy in complex, unresolved, and exhaustion-phase disease states. While systemic platelet-based therapies remain investigational, this conceptual synthesis broadens current understanding of platelet function, lays the groundwork for future mechanistic studies, standardized dosing strategies, and rigorous clinical investigation, and underscores the need for continued empirical validation to determine the therapeutic scope and limitations of this model.

References

[1] R. K. Naviaux, "Mitochondrial and metabolic features of salugenesis and the healing cycle," *Mitochondrion, 70,* pp. 131-163, 2023.
[2] B. Chu, K. Marwaha, T. Sanvictores, A. O. Awosika and D. Ayers, Physiology, stress reaction, StatPearls, 2025.
[3] H. Yamasaki, R. Naomasa, K. Mizumoto and M. Cohen, "The three body problem in stress biology: The balance between O_2, NO, and H_2S in the context of Hans Selye's stress concept," *Stresses, 5(2), 37,* p. 37, 2025.
[4] H. Selye, "A syndrome produced by diverse nocous agents," *Nature, 138, 32,* 1936.
[5] H. Selye, The Stress of Life, McGraw-Hill, 1956.
[6] B. McEwen, "Physiology and neurobiology of stress and adaptation," *Physiological Reviews,* pp. 873-904, 2007.
[7] R. M. Sapolsky, L. M. Romero and A. U. Munck, "How do glucocorticoids influence stress responses?," *Endocrine Reviews, 21(1),* pp. 55-89, 2000.
[8] J. P. Herman, J. M. McKlveen, S. Ghosal, B. Kopp, A. Wulsin, R. Makinson, J. Scheimann and B. Myers, "Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response," *Comprehensive Physiology, 6(2),* pp. 603-621, 2016.
[9] F. Dhabhar, "Stress-induced augmentation of immune function," *Brain, Behavior, and Immunity, 16(6),* pp. 55-89, 2002.
[10] S. Fulda, A. M. Gorman, O. Hori and A. Samali, "Cellular stress responses," *International Journal of Cell Biology,* 2010.
[11] S. Lindquist and E. A. Craig, "The heat-shock proteins," *Annual Review of Genetics, 22,* pp. 631-677, 1988.
[12] B. McEwen and J. Wingfield, "The concept of allostasis in biology and biomedicine," *Hormones and Behavior, 43(1),* pp. 2-15, 2003.
[13] W. Dröge, "Free radicals in the physiological control of cell function," *Physiological Reviews, 82(1),* pp. 47-95, 2002.
[14] H. Sies and D. Jones, "Reactive oxygen species (ROS) as pleiotrophic physiological signaling agents," *Nature Review Molecular Cell Biology, 21,* pp. 363-383, 2020.
[15] G. C. Gurtner, S. Werner, Y. Barrandon and M. T. Longaker, "Wound repair and regeneration," *Nature, 453,* pp. 314-321, 2008.
[16] M. Perretti and F. D'Acquisto, "Annexin A1 and glucocorticoids as effectors of the resolution of inflammation," *Nature Reviews Immunology, 9,* pp. 62-70, 2009.
[17] T. Rhen and J. Cidlowski, "Anti-inflammatory action of glucocorticoids-new mechanisms," *New England Journal of Medicine, 353,* pp. 1711-1723, 2005.
[18] C. Nathan and A. Ding, "Nonresolving inflammation," *Cell, 140(6),* pp. 871-882, 2010.

[19] N. Mizushima and B. Levine, "Autophagy in mammalian development and differentiation," *Nature Cell Biology, 12,* pp. 823-830, 2010.
[20] M. Picard, B. S. McEwen and E. S. S. C. Epel, "An energetic view of stress: Focus on mitochondria," *Frontiers in Neuroendocrinology, 49,* pp. 72-85, 2018.
[21] M. Kobayashi and M. Yamamoto, "Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation," *Antioxidants & Redox Signaling, 7(3-4),* pp. 385-394, 2005.
[22] Q. Ma, "Role of Nrf2 in oxidative stress and toxicity," *Annual Review of Pharmacology and Toxicology, 53,* pp. 401-426, 2013.
[23] G. E. Miller, E. Chen and E. S. Zhou, "If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans," *Psychological Bulletin, 134,* pp. 25-45, 2008.
[24] R. Glaser and J. K. Kiecolt-Glaser, "Stress-induced immune dysfunction," *Nature Reviews Immunology, 5,* pp. 243-251, 2005.
[25] F. S. Dhabhar, "Effects of stress on immune function: The good, the bad, and the beautiful," *Immunologic Research, 58,* pp. 193-210, 2014.
[26] S. L. Spinelli, A. E. Casey, S. J. Pollock, J. M. Gertz, D. H. McMillan, S. D. Narasipura, N. A. Mody, M. R. King, S. B. Maggirwar, C. W. Francis, N. Blumberg and R. P. Phipps, "Platelets and megakaryocytes contain functional nuclear factor-kappa B," *Arteriosclerosis, Thrombosis, and Vascular Biology, 30(3),* pp. 591-598, 2010.
[27] M. J. Meaney and M. Szyf, "Environmental programming of stress responses through DNA methylation," *Molecular Psychiatry, 10,* pp. 12-24, 2005.
[28] Zannas and G. Chrousos, "Epigenetic programming by stress and glucocorticoids along the human lifespan," *Molecular Psychiatry, 22(5),* pp. 640-646, 2017.
[29] M. Picard and B. McEwen, "Physiological Stress and Mitochondria: A Conceptual Framework," *Psychosomatic medicine, 80(2),* pp. 126-140, 2018.
[30] J. Campisi, "Aging, cellular senescence, and cancer," *Annual Review of Physiology, 75,* pp. 685-705, 2013.
[31] J. Coppé, P. Y. Desprez, A. Krtolica and J. Campisi, "The senescence-associated secretory phenotype: The dark side of tumor suppression," *Annual Review of Pathology, 5,* pp. 99-118, 2010.
[32] C. López-Otín, M. A. Blasco, L. Partridge, M. Serrano and G. Kroemer, "The hallmarks of aging," *Cell, 153,* pp. 1194-1217, 2013.
[33] Panossian and G. Wikman, "Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity," *Pharmaceuticals 3(1),* pp. 188-224, 2010.
[34] G. Panossian, T. Efferth, A. N. Shikov, O. N. Pozharitskaya, K. Kuchta, P. K. Mukherjee, S. Banerjee, M. Heinrich, W. Wu, D. A. Guo and H. Wagner, "Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress and aging-related diseases," *Medicinal research reviews, 41(1),* pp. 630-703, 2021.
[35] Panossian, "Understanding adaptogenic activity: Specificity of the pharmacological action of adaptogens and other phytochemicals," *Annals of the New York Academy of Sciences, 1299,* pp. 49-64, 2013.
[36] K. Auyeung, Q. Han and J. Ko, "Astragalus membranaceus: A review of its protection against inflammation and gastrointestinal cancers," *American Journal of Chinese Medicine, 44(1),* pp. 1-22, 2016.
[37] G. Singh, P. Sharma, R. Dudhe and S. Singh, "Biological activites of Withania somnifera," *Annals of Biological Research, 1(3),* pp. 56-63, 2010.
[38] K. Chandrasekhar, J. Kapoor and S. Anishetty, "A prospective, randomized double-blind, placebo controlled study of safety and efficacy of a high-concentration full spectrum extract of ashwagandha root in reducing stress and anxiety in adults," *Indian journal of psychological medicine, 34(3),* pp. 255-262, 2012.
[39] G. Burnstock, "Purinergic signaling: from discovery to current developments," *Experimental Physiology, 99(1),* pp. 16-34, 2014.
[40] F. Di Virgilio, D. Dal Ben, A. Sarti, A. Giuliani and S. Falzoni, "The P2X7 receptor in infection and inflammation," *Immunity, 47(1),* pp. 15-31, 2017.
[41] K. Gohil, B. C. Schock, A. A. Chakraborty, Y. Terasawa, J. Raber, R. V. Farese and L. Packer, "Gene expression profile of oxidant stress and neuroprotection: Modulatory role of vitamin E," *Proceedings of the National Academy of Sciences of the United States of America, 102(15),* pp. 5302-5307, 2005.
[42] K. Machlus and J. J. Italiano, "The incredible journey: From megakaryocyte development to platelet formation," *Journal of Cell Biology, 201(6),* pp. 785-796, 2013.
[43] S. Jackson, "Arterial thrombosis-insidious, unpredictable and deadly," *Nature Medicine, 17(11),* pp. 1423-1436, 2011.
[44] P. Everts, K. Onishi, P. Jayaram, J. F. Lana and K. Mautner, "Platelet rich plasma: new performance understanding and therapeutic considerations in 2020," *International journal of molecular sciences, 21(20) 7794,* 2020.
[45] Kia, J. Baldino, R. Bell, A. Ramji, C. Uyeki and A. Mazzocca, "Platelet rich plasma: review of current literature on its use for tendon and ligament pathology," *Current reviews in musculoskeletal medicine, 11(4) ,* pp. 566-572, 2018.
[46] M. G. Buontempo, L. Alhanshali, J. Shapiro, K. L. Sicco and M. S. Garshick, "Platelet rich plasma applications, the past 5 years: A review article," *European Medical Journal,* 2023.
[47] J. Barnett, M. Borin, L. Barry, E. Katayama, A. Patel, G. Cvetanovich, J. Bishop and R. Rauck, "The utility of platelet rich plasma in modern orthopedic practices: a review of the literature," *Journal of Orthopaedic Experience & Innovation, 5 (1),* 2024.
[48] J. N. Pixley, M. K. Cook, R. Singh, J. Larrondo and A. J. McMichael, "A comprehensive review of platelet rich plasma for the treatment of dermatologic disorders," *Journal of Dermatological Treatment, 34(1),* 2023.
[49] Arita and M. Tobita, "Adverse events related to platelet-rich plasma therapy and future issues to be resolved," *Regenerative Therapy, Vol. 26,* pp. 496-501, 2024.
[50] Z. Ruggeri, "Platelets in atherothrombosis," *Nature Medicine, 8(11),* pp. 1227-1234, 2002.

[51] T. Gremmel, A. Frelinger and A. Michelson, "Platelet physiology," *Seminars in Thrombosis and Hemostasis, 42(3),* pp. 191-204, 2016.

[52] J. E. Italiano, R. J. L. Jr., S. Patel-Hett, E. Battinelli, A. Zaslavsky, S. Short, S. Ryeom, J. Folkman and G. L. Klement, "Angiogenesis is regulated by a novel mechanism: Pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released," *Blood, 111(3),* pp. 1227-1233, 2008.

[53] J. Semple, J. Italiano and J. Freedman, "Platelets and the immune continuum," *Nature Reviews Immunology, 11(4),* pp. 264-274, 2011.

[54] P. Vachon, C. Lecut and J. Freedman, "Platelet intracellular signaling: Regulation of energy metabolism, vesicle formation, and stress adaptation," *Journal of Thrombosis and Haemostasis, 22(1) ,* pp. 61-75, 2024.

[55] J. Italiano, P. Lecine, R. Shivdasani and J. Hartwig, "Mechanisms and regulation of platelet secretion," *Arteriosclerosis, Thrombosis, and Vascular Biology, 28(3),* pp. s15-s20, 2008.

[56] T. Li, W. Wang, Z. Qin, Y. Chen, K. Zhu, H. Liu, J. Sun and H. Zhong, "Extracellular vesicles in cardiovascular diseases: Pathogenic mediators, diagnostic tools, and therapeutic vectors," *Frontiers in Cardiovascular Medicine, 12 Article 1666589,* 2025.

[57] M. Klinger and W. Jelkmann, "Role of platelets in inflammation," *Platelets, 13(5-6),* pp. 325-334, 2002.

[58] Bellezza, I. Giambanco, A. Minelli and R. Donato, "Nrf2-Keap1 signaling in oxidative and reductive stress. Biochimica et Biophysica Acta (BBA)," *Molecular Cell Research, 1865(5),* pp. 721-733, 2018.

[59] S. Spinelli, P. Gresele and M. de Angelis, "NF-kB in platelets: Modulation of inflammatory responses and immune signaling," *Journal of Thrombosis and Haemostasis, 8(12),* pp. 2720-2728, 2010.

[60] Wingfield, "Control of behavioural strategies for capricious environments," *Animal Behaviour, 66(5),* pp. 807-816, 2003.

[61] Franceschi, P. Garagnani, P. Parini, C. Giuliani and A. Santoro, "Inflammaging: A new immune-metabolic viewpoint for age-related diseases," *Nature Reviews Endocrinology, 14(10),* pp. 576-590, 2018.

[62] T. Squillaro, G. Peluso and U. Galderisi, "Clinical Trials with mesenchymal stem cells: An update," *Cell Transplantation, 25(5),* pp. 829-848, 2016.

[63] N. L. Handly, A. Pilko and R. Wollman, "Paracrine communication maximizes cellular response fidelity in wound signaling," *eLife, 4:e09652,* 2015.

[64] Thomas, S. Rahmanian, A. Bordbar, B. Palsson and N. Jamshidi, "Network reconstruction of platelet metabolism identifies metabolic signature for aspirin resistance," *Scientific Reports, 4,* p. 3925, 2014.

[65] Y. Li, H. You, C. Ou, H. Zhu, B. Cheng and J. Tian, "The evolution of three generations of platelet concentrate products: a leap from classical formulations to the era of extracellular vesicles," *Frontiers in Bioengineering and Biotechnology, 13,* p. 1628565, 2025.

[66] T. Burnouf, M. Chou, D. Lundy and e. al., "Expanding applications of allogenic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery," *Journal of Biomedical Science, 30,* p. 79, 2023.

[67] Ray, S. Spinelli, S. Pollock, T. Murant, J. O'Brien, N. Blumberg, C. Francis and R. Phipps, "Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles," *Thrombosis and Haemostasis, 99(1),* pp. 86-95, 2008.

[68] H. Y. Liu, C. F. Huang, T. C. Lin, C. Y. Tsai, S. Y. Tina Chen, A. Liu, W. H. Chen, H. J. Wei, M. F. Wang, D. F. Williams and W. P. Deng, "Delayed animal aging through the recovery of stem cell senescence by platelet rich plasma," *Biomaterials, 35(37),* pp. 9767-9776, 2014.

[69] U. Congress, "21st Century Cures Act. Pub. L No. 114-255," Vols. https://www.congress.gov/bill/114th-congress/house-bill/34, December 13, 2016.

[70] USFDA, "U.S Food and Drug Administration. Regenerative Medicine Advanced Therapy (RMAT) Designation. FDA Guidance. Updated 2022," Vols. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation.

[71] N. Demir, F. Kaymaz, M. Kocaturk and B. Bilgic, "Intravenous allogenic platelet-rich plasma improves cognitive performance in aged mice," *Aging Brain Research, 15,* pp. 45-53, 2020.

[72] Alcaraz, A. Oliver, and J.M. Sánchez, "Platelet-Rich Plasma in a Patient with Cerebral Palsy," *The American journal of case reports*, *16*, 469–472, 2015.

[73] J. Yang, L. Chen, Q. Zhu, R. Wang and H. Li, "Systemic administration of platelet-rich plasma reduces infarct volume and promotes functional recovery after focal cerebral ischemia in rats," *NeuroReport, 26(14),* pp. 795-801, 2015.

[74] Angelone, D. Bizzaro, L. Mura and et. al., "Regional intravenous perfusion of platelet-rich plasma combined with adipose-derived mesenchymal stem cells in equine chronic laminitis," *Veterinary Immunology and Immunopathology, 186,* pp. 1-8, 2017.

[75] Karina, L. M. Christoffel, R. Novariani, I. Rosadi, I. Rosliana, S. Rosidah, S. Sobariah, N. Fatkhurohman, N. Puspitaningrum, Y. Hertati, I. Afini, D. Ernanda, T. Widyastuti, A. D. Sulaeha, A. Zakiyah, N. Aini, G. Krisandi and H. Andrew, "The effect of intravenous autologous activated platelet-rich plasma therapy on "profibrotic cytokine" IL-1B levels in severe and critical COVID-19 patients: A preliminary study," *Scientifica,* p. 9427978, 2021.

[76] G. S. Kelly, S. Dowling and M. Bechtel, "Rhodiola rosea: a review of its dose-dependent effects on stress adaptation and clinical applications," *Journal of Alternative and Complementary Medicine, 19(5),* pp. 356-362, 2013.

[77] Anitua, M. Sanchez, G. Orive and I. Andia, "Delivering growth factors for therapeutics: systemic versus local effects of platelet-rich plasma," *Thrombosis and Haemostasis, 99(3),* pp. 453-461, 2008.